$CMPD
$UURAF $UCU
UCORE RARE METALS INC.
JACK LIFTON, ONE OF THE WESTERN WORLD'S FOREMOST RARE EARTH EXPERTS, SAYS NEARLY ALL RARE EARTH JUNIORS CLAIMING "MINE-TO-MAGNET" INTEGRATION ARE UNREALISTIC. HEAVY RARE EARTHS ONLY ACQUIRE VALUE AFTER SEPARATION, PURIFICATION, METALLIZATION AND CUSTOMER QUALIFICATION. THESE ARE INDUSTRIAL MILESTONES, NOT FINANCIAL ONES. UCORE DELIBERATELY CHOSE ANOTHER ROUTE BY FOCUSING ON SEPARATION WITH RAPIDSX, THE GREATEST TECHNICAL BOTTLENECK OUTSIDE CHINA. UCORE HAS NOW PRODUCED A 99.9% PURE DYSPROSIUM OXIDE SAMPLE AND DELIVERED IT TO A CUSTOMER. LIFTON ALSO HIGHLIGHTS THE SUMITOMO → UCORE → PHOENIX TAILINGS SUPPLY CHAIN. IF UCORE SUCCEEDS, IT WON'T NEED THE WORLD'S BEST MINE. IT COULD BECOME THE PROCESSOR THAT MANY MINES NEED. CEO PAT RYAN'S STRATEGY ECHOES ROCKEFELLER: "YOU DON'T MAKE MONEY DRILLING FOR OIL. YOU MAKE MONEY CONTROLLING THE REFINING PROCESS."
https://investornews.com/critical-minerals-rare-earths/jack-in-the-stox-ucore-and-the-rare-earth-separation-bottleneck/
$CMPD $13.50 $3.15 SELL/ TAKE PROFIT ON 10% AS PARTIAL SELL TO REDUCE COST TO ZERO ... from DAC (dollar average cost) (2) $3.18.
CHANGE EXIT TO $22.00 long term
https://stocktwits.com/G101SPM/message/618661000
UPDATE: FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data
CNPV awarded for COMP360 in TRD, further accelerating momentum
26-week (Part B) data from COMP006, expected in early Q3 2026
Final NDA submission on track for Q4, aligned with Company’s previously defined accelerated timing to be launch ready by end of year
Successful financing and warrant exercises resulted in strong cash position of $466 million at end of first quarter, providing cash runway well beyond launch and into 2028
$CMPD $AGILQ $MRVL 🔥 MYNZ PR OUT 🚨 MarketBeat $120 PT (+3,000%) + Jonestrading $440 PT (+12,000%) Here is why:
🔥 NEWS: Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
DGX to distribute NextGen nationwide (18-mo option), $8M to fast-track FDA, TMO co-developing mRNA-based CRC screening. Supporters: P. Starke, G. Starke, F. Muniz. Low float, $50 soon! 🔥
I found you a MACD Bearish Reversal Divergence on the daily chart of CompuMed Inc. $CMPD #CMPD #macd #divergence #pink #tradingsignals #technicalanalysis
$CMPD CompuMed Integrates the Techcyte Digital Pathology Reviewing Platform to Help Increase Transplanted Organs
https://www.stocktitan.net/news/CMPD/compu-med-integrates-the-techcyte-digital-pathology-reviewing-zduby4im7jqv.html
$CMPD [15s. delayed]: Issued Press Release on June 12, 16:30:00: CompuMed Announces Purchase of Shares held by VI Capital and Changes in t https://s.flashalert.me/SJx6j6
$CMPD CompuMed Announces Purchase of Shares held by VI Capital and Changes in the Board of Directors
https://www.stocktitan.net/news/CMPD/compu-med-announces-purchase-of-shares-held-by-vi-capital-and-01w5xdv72o4b.html
$CMPD [15s. delayed]: Issued Press Release on May 25, 17:35:00: CompuMed Announces Approval and Amendment to Reduce Authorized Shares https://s.flashalert.me/UgSlo
$CMPD [15s. delayed]: Issued Press Release on March 22, 11:00:00: CompuMed CEO Lee Keddie Joins The Alliance National Innovation Leadershi https://s.flashalert.me/UlrlW
$CMPD CompuMed CEO Lee Keddie Joins The Alliance National Innovation Leadership Council
https://www.stocktitan.net/news/CMPD/compu-med-ceo-lee-keddie-joins-the-alliance-national-innovation-fnrylkvx2azn.html
$CMPD [15s. delayed]: Issued Press Release on December 27, 17:00:00: Compumed, Inc. Announces Fiscal 2022 Annual and Fourth Quarter Result https://s.flashalert.me/ZnMCw
